Brainomix raises funding to deploy AI imaging for stroke triage, fibrosis detection
This article covers Brainomix, an Oxford-founded healthtech startup, which has raised a £4.8m extension to its series C funding round, taking the round total to £18.8m. The funding is intended to accelerate the startup's US expansion and hospital deployments of its AI imaging platforms for stroke and lung fibrosis, supporting clinicians and patient care pathways.
Brainomix, an Oxford-founded healthtech startup, has raised a £4.8 million extension to its series C funding round, bringing the round total to £18.8 million after a prior £14 million close in March 2025. The fresh capital — led by existing investors Parkwalk Advisors and Hostplus and joined by new US backer Modi Ventures — is earmarked to accelerate US expansion and hospital deployments of Brainomix’s AI imaging platforms for stroke and lung fibrosis.
Why it matters
AI imaging is becoming a practical tool in time-sensitive care pathways. For stroke, faster and more accurate imaging can influence whether a patient is routed to endovascular thrombectomy, a treatment with a narrow time window. For pulmonary fibrosis, earlier detection and consistent monitoring can change therapy choices and long-term outcomes.
The funding therefore matters not only as a financing milestone for a University of Oxford spinout, but as a signal that institutional and venture investors continue to back clinical AI products that are already cleared by regulators and moving into routine hospital use, particularly in the US market.
Inside the product
Brainomix’s two core products are Brainomix 360 Stroke and Brainomix 360 e-Lung. The Stroke platform automates acute stroke assessment across the patient pathway, aiming to standardise triage and support transfer and treatment decisions even in centres with limited specialist expertise. The company says its tools are among a portfolio of FDA-cleared AI imaging solutions and are in use in more than 20 countries.
e-Lung applies AI to chest CT scans to extract biomarkers linked to fibrosing lung disease. The goal is earlier identification and longitudinal monitoring to inform clinical decisions and track progression.
Both products focus on integrating with existing clinical workflows rather than replacing clinicians, a practical approach for adoption in busy hospital settings.
Who are the investors?
The £4.8 million extension was led by returning investors Parkwalk Advisors and Hostplus through the IP Group Hostplus Innovation Fund, with participation from new US investor Modi Ventures. The additional capital increases the company’s series C to a reported £18.8 million in total.
Parkwalk is described as the UK’s largest growth EIS fund manager, specialising in university spinouts and early-stage deeptech companies. Hostplus is a major Australian industry superannuation fund with roughly AUD$140 billion in assets under management, representing institutional interest from outside Europe. Modi Ventures is an early-stage US venture capital firm that invests in healthtech, tech bio and artificial intelligence.
In the announcement, Sahir Ali, founder and general partner of Modi Ventures, said:
Brainomix has built an exceptionally strong platform backed by rigorous clinical validation and real-world evidence showing that Brainomix 360 Stroke can significantly increase endovascular thrombectomy treatment rates and reduce delays in patient triage and transfer, particularly in primary stroke centers. With e-Lung, Brainomix is developing a truly novel technology to accelerate the diagnosis of fibrosing lung disease, enabling earlier treatment options that can improve patient outcomes. We are pleased to join as a new investor and look forward to supporting the company as it expands in the U.S. and accelerates adoption of technologies that meaningfully improve patient outcomes.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
In the announcement, Dr Michalis Papadakis, CEO and co-founder of Brainomix, said:
This investment reflects strong confidence in our technology, our team, and the impact Brainomix 360 Stroke and e-Lung can have on patient care. Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time, underscoring the need for hospital technologies that support clinicians at the point of care. With this investment extension, we are well-positioned to enhance customer support across the US and Europe, accelerating the seamless integration of our technology into existing clinical workflows and expanding access to life-saving treatments.
Papadakis’s comments frame the raise as operationally focused: more resource for customer support, workflow integration and scaling deployments rather than purely product development.
The bigger picture
The deal illustrates several broader trends in the UK and European healthtech market. First, university-originated medtech and AI companies continue to attract follow-on capital when products reach regulatory clearance and real-world adoption. Second, cross-border investor participation — here from an Australian pension fund and a US VC — shows institutional and strategic appetite for clinical AI businesses that can address large healthcare markets.
For UK healthtech startups, the path to scale often runs through the US, where hospital systems and reimbursement models can support faster commercial traction for imaging and diagnostics. At the same time, backing from funds like Parkwalk signals that UK tax-incentivised vehicles remain an important part of the funding mix for university spinouts.
The extension to Brainomix’s series C underscores how clinical validation, regulatory milestones and a clear go-to-market plan can unlock continued investment as companies move from lab and pilot stages to broader hospital deployment across the US and Europe.
They've invested in Brainomix
Get to know these healthtech investors
Click here for a full list of 7,526+ startup investors in the UK